Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Larimar Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.18
20.09.22
€7.00
31.08.25
32.08%
05.05.23

Could be very worthwhile Investment >20% year
buy
Minerva Neurosciences Inc.

Start price
Target price
Perf. (%)
€8.64
19.09.22
€17.00
19.09.23
-34.41%
17.10.22

Could be very worthwhile Investment >20% year
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€1.21
19.09.22
-
19.09.23
-12.19%
01.10.22

Capable Management
Could be very worthwhile Investment >20% year
Few uniques
Vivani Medical Inc.

Start price
Target price
Perf. (%)
€2.81
19.09.22
-
19.09.23
-67.84%
24.04.23

Probably not worthwhile Investment
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€6.20
19.09.22
-
19.09.23
-18.43%
08.11.22

Could be worthwhile Investment >10% per year
Very high cyclical dependencies
buy
Abbott Laboratories

Start price
Target price
Perf. (%)
€103.36
19.09.22
€130.00
19.09.23
-8.59%
20.09.23

Could be worthwhile Investment >10% per year
High dividend yield expected
Revenue growth >5% per year expected
Top 10 in its market
buy
Athersys Inc.

Start price
Target price
Perf. (%)
€1.87
19.09.22
€3.80
19.09.23
0.19%
17.10.22

Could be very worthwhile Investment >20% year
buy
Albireo Pharma Inc.

Start price
Target price
Perf. (%)
€16.96
18.09.22
-
18.09.23
144.16%
18.05.23

Risky Investment
buy
Intercept Pharmaceuticals

Start price
Target price
Perf. (%)
€17.43
18.09.22
-
18.09.23
-17.30%
01.10.22

Risky Investment
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€1.65
18.09.22
-
18.09.23
-3.77%
01.10.22

Risky Investment
Palatin Technologies Inc.

Start price
Target price
Perf. (%)
€7.79
17.09.22
€3.00
17.09.23
-22.91%
01.10.22

High valuation
Bad rating
Little Investments for future growth
ROE lower than 10% per year
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€64.59
16.09.22
-
16.09.23
9.92%
16.09.23

Akero Therapeutics Inc

Start price
Target price
Perf. (%)
€26.40
15.09.22
€8.00
15.09.23
-1.52%
17.09.22

Revenue growth >5% per year expected
Probably not worthwhile Investment
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Akero Therapeutics Inc

Start price
Target price
Perf. (%)
€26.40
15.09.22
€11.00
15.09.23
-1.52%
17.09.22

Differentiated customer and product portfolio
High valuation
High risks in the balance sheet
Increased challenges to pay loans and raise capital
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€309.00
15.09.22
€550.00
15.09.23
74.76%
16.09.23

buy
Athersys Inc.

Start price
Target price
Perf. (%)
€2.21
15.09.22
€4.60
15.09.23
-15.60%
19.09.22

Could be very worthwhile Investment >20% year
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€1.62
14.09.22
-
14.09.23
1.70%
17.09.22

Risky Investment
buy
Bayer AG

Start price
Target price
Perf. (%)
€54.25
14.09.22
€65.00
14.09.23
-3.93%
17.09.22

buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€2.62
13.09.22
-
13.09.23
-37.10%
17.09.22

Could be very worthwhile Investment >20% year
buy
G1 Therapeutics

Start price
Target price
Perf. (%)
€15.76
13.09.22
-
13.09.23
-90.26%
13.09.23

InMed Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€16.34
12.09.22
-
12.09.23
-93.70%
02.04.23

Could be very worthwhile Investment >20% year
buy
Akero Therapeutics Inc

Start price
Target price
Perf. (%)
€11.50
09.09.22
-
09.09.23
266.96%
18.05.23

Risky Investment
buy
Axsome Therapeutics Inc

Start price
Target price
Perf. (%)
€60.00
08.09.22
€80.00
31.12.24
35.00%
24.06.23

Could be very worthwhile Investment >20% year
buy
Reata Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€25.60
08.09.22
€40.00
31.12.24
35.94%
21.10.22

Could be very worthwhile Investment >20% year
buy
Ardelyx Inc.

Start price
Target price
Perf. (%)
€1.29
08.09.22
€2.00
31.12.24
31.25%
09.12.22

Could be very worthwhile Investment >20% year